NVOH - ETF AI Analysis

Top Page

Novo Nordisk A/S (B Shares) ADRhedged (NVOH)

Rating:70Neutral

Price Target:―

NVOH is an ETF whose rating reflects generally solid quality, largely driven by its heavy exposure to Novo Nordisk (NVO), which dominates the fund and brings strong financial performance, a reasonable valuation, and a focus on long-term growth and dividends. However, the fund’s score is held back somewhat by Novo Nordisk’s bearish technical signals and challenges like market share pressure and restructuring, and the main risk is the very high concentration in a single stock and company-specific developments.

Positive Factors

Strong Recent Performance

The ETF has shown strong gains over the year and in recent months, indicating solid recent momentum.

Low Expense Ratio

The fund charges a relatively low fee, which helps investors keep more of their returns over time.

Focused Exposure to a Strong Holding

The ETF is heavily invested in Novo Nordisk, which itself has delivered strong year-to-date performance, supporting the fund’s results.

Negative Factors

Extreme Single-Stock Concentration

Nearly all of the fund’s assets are in one company, meaning the ETF’s performance is highly dependent on that single stock.

Sector Concentration in Health Care

With almost all exposure in the health care sector, the fund is vulnerable to downturns or regulatory changes affecting that industry.

Limited Geographic Diversification

The ETF is almost entirely tied to the U.S. market, offering little protection if that market faces a broad decline.

NVOH vs. SPDR S&P 500 ETF (SPY)

AUM3.80M

RegionEurope

Expense Ratio0.19%

Beta1.12

IssuerADRhedged

Inception DateJan 07, 2025

Dividend Yield3.05%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume8,840

30 Day Avg. Volume8,183

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

23.97

Price Target Upside― Downside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

NVOH Summary

NVOH is an ETF that focuses almost entirely on Novo Nordisk, a major global healthcare and pharmaceutical company known for its diabetes and obesity treatments. It doesn’t track a broad index, but instead gives targeted exposure to this single leader in the health care and pharmaceuticals space, while using a currency hedge to reduce the impact of foreign exchange swings for U.S. investors. Someone might invest for potential growth tied to rising demand for treatments for chronic diseases. The main risk is that the fund is concentrated in one company, so its value can rise or fall sharply with Novo Nordisk’s fortunes.

How much will it cost me?The NVOH ETF has an expense ratio of 0.19%, which means you’ll pay $1.90 per year for every $1,000 invested. This is lower than average for actively managed funds, as it focuses on a specific company and niche within the healthcare sector, keeping costs relatively modest.

What would affect this ETF?The NVOH ETF could benefit from the growing global demand for innovative healthcare solutions, particularly in diabetes and obesity treatments, areas where Novo Nordisk is a leader. However, potential risks include regulatory changes in the pharmaceutical industry or shifts in healthcare policies that could impact drug pricing and market access. Additionally, while the fund mitigates currency risk, broader economic challenges in Europe or Denmark could still influence its performance.

NVOH Top 10 Holdings

This ETF is essentially a one-stock story: Novo Nordisk dominates the portfolio and sets the tone for performance. Lately, the pharma giant has been treading water, with its share price looking more tired than triumphant despite solid long-term fundamentals and a strong position in diabetes and obesity treatments. That means the fund’s returns have been lagging rather than lifted, with no other holdings to pick up the slack. It’s a highly concentrated bet on European, Denmark-based health care, not a diversified basket of global drugmakers.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
NVO	Novo Nordisk	95.92%	$3.68M	$171.65B	-48.08%	73 Outperform

NVOH Technical Analysis

Technical Analysis Sentiment

Negative

Last Price―

Price Trends

50DMA

27.17

Negative

100DMA

26.99

Negative

200DMA

29.94

Negative

Market Momentum

MACD

-1.77

Negative

RSI

36.88

Neutral

STOCH

77.96

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For NVOH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 22.73, equal to the 50-day MA of 27.17, and equal to the 200-day MA of 29.94, indicating a bearish trend. The MACD of -1.77 indicates Negative momentum. The RSI at 36.88 is Neutral, neither overbought nor oversold. The STOCH value of 77.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NVOH.

NVOH Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
NVOH	―	―	$3.80M	0.19%	70 Neutral
LFSC	―	―	$95.01M	0.54%	55 Neutral
FMED	―	―	$59.37M	0.50%	60 Neutral
OZEM	―	―	$56.44M	0.59%	61 Neutral
ARMH	―	―	$1.01M	0.19%	67 Neutral
STHH	―	―	$674.21K	0.19%	56 Neutral

Performance Comparison

NVOH

Novo Nordisk A/S (B Shares) ADRhedged

21.43

-20.39

-48.76%

LFSC

F/M Emerald Life Sciences Innovation ETF

―

FMED

Fidelity Disruptive Medicine ETF

―

OZEM

Roundhill GLP-1 & Weight Loss ETF

―

ARMH

Arm Holdings PLC ADRhedged

―

STHH

STMicroelectronics NV ADRhedged

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents